Is An End To The Combination Therapy Pricing Problem In Sight In The UK?
Executive Summary
Indication-based pricing and tackling complications caused by competition law could help the UK catch up with other countries when it comes to market access for combination therapies.
You may also be interested in...
Brazilian Regulator Extends COVID-19 Measures
Brazil’s medicines regulator is extending COVID-19 era resolutions designed to speed up its evaluation of clinical research in Brazil.
Canada Publishes Real World Evidence Guidance For HTA And Regulatory Decision Making
The new guidance was drawn up through extensive engagement with national and international experts in RWD and RWE, as well as stakeholders in Canada.
EU Pharma Revision Of Hospital Exemptions For ATMPs 'Is Unsatisfactory'
The EU legislative overhaul falls short on dealing with the issue of hospital exemptions for advanced therapies, says the Alliance For Regenerative Medicine.